{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0000318154","name":"AMGEN INC","summary":"Amgen Inc. is a leading independent biotechnology company that discovers, develops, manufactures, and delivers innovative human therapeutics. Founded in 1980, it operates in approximately 100 countries and focuses on areas of high unmet medical need. Key products include Prolia, XGEVA, Repatha, Otezla, TEZSPIRE, TEPEZZA, KRYSTEXXA, UPLIZNA, IMDELLTRA, and MariTide, targeting cardiovascular disease, osteoporosis, inflammation, oncology, and rare diseases.","people":[],"products":[{"name":"Prolia","type":"service","description":"RANKL antibody for treatment of osteoporosis in postmenopausal women and men at high risk of fracture."},{"name":"XGEVA","type":"service","description":"Same active ingredient as Prolia but approved for different oncology-related bone indications."},{"name":"Repatha","type":"service","description":"PCSK9 inhibitor indicated to reduce major adverse cardiovascular events and LDL-C in adults."},{"name":"Otezla","type":"service","description":"Oral PDE4 inhibitor approved for plaque psoriasis, psoriatic arthritis, Behçet's disease oral ulcers."},{"name":"TEZSPIRE","type":"service","description":"Biologic approved as add-on maintenance for severe asthma and chronic rhinosinusitis with nasal polyps."},{"name":"TEPEZZA","type":"service","description":"Treatment for moderate-to-severe thyroid eye disease; acquired via Horizon acquisition in 2023."},{"name":"KRYSTEXXA","type":"service","description":"Treatment product acquired through Horizon acquisition in October 2023."},{"name":"UPLIZNA","type":"service","description":"First and only FDA-approved treatment for IgG4-RD; also approved for generalized myasthenia gravis in adults."},{"name":"IMDELLTRA/IMDYLLTRA","type":"service","description":"Bispecific T-cell engager fully approved for extensive-stage small cell lung cancer after platinum-based chemotherapy."},{"name":"TAVNEOS","type":"service","description":"Adjunctive treatment for severe active ANCA-associated vasculitis; subject to FDA voluntary withdrawal request in 2026."},{"name":"MariTide (maridebart cafraglutide)","type":"service","description":"Antibody-peptide conjugate activating GLP-1 and antagonizing GIPR; in Phase 3 for chronic weight management and related conditions."},{"name":"Bemarituzumab","type":"service","description":"Investigated in Phase 3 for first-line gastric cancer; company decided not to pursue regulatory approval in 2026."},{"name":"Rocatinlimab","type":"service","description":"Collaboration with Kyowa Kirin; control transitioned to Kyowa Kirin in early 2026."}],"partnerships":[{"partner_name":"Astellas Pharma Inc.","partnership_type":"strategic","description":"Partnership to sell products in the Asia Pacific region.","start_date":null},{"partner_name":"BeOne","partnership_type":"strategic","description":"Partnership to sell products in the Asia Pacific region.","start_date":null},{"partner_name":"Mitsubishi Tanabe Pharma Corporation","partnership_type":"strategic","description":"Partnership to sell products in the Asia Pacific region.","start_date":null},{"partner_name":"Takeda Pharmaceutical Co., Ltd.","partnership_type":"strategic","description":"Partnership to sell products in the Asia Pacific region.","start_date":null},{"partner_name":"Kyowa Kirin","partnership_type":"strategic","description":"Asia Pacific product sales partner; also assumed global control of rocatinlimab development and commercialization in 2026.","start_date":null},{"partner_name":"Bristol Myers Squibb Company","partnership_type":"licensing","description":"Amgen acquired Otezla from BMS in November 2019 following BMS's acquisition of Celgene.","start_date":null}],"affiliations":[],"origin":{"leaf":"3b47ba2f8e7165b5f567da5ab485e3fb516320b7b4485373685715ef393704f1","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"8604eaf263e30a70777a483b596b509f29d2aaff522779d15768f0709f748a7c","parent":"69af5a8b316dadfb67cbbe68409cfff4bbd89d7a694688b2dffe8dd87cd02bd3","source":"0000318154-26-000010","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":6,"hourly_limit":500,"remaining":494,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}